Go Pro
→ The ultimate IPO unicorn (From Weiss Ratings) (Ad)tc pixel Free OCSAW Stock Alerts

Oculis (OCSAW) Competitors

Oculis logo
$4.50 0.00 (0.00%)
As of 08/7/2026
Compare

OCSAW vs. SXTPW, DRTSW, APLMW, BIVIW, and CDIOW

Should you buy Oculis stock or one of its competitors? MarketBeat compares Oculis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oculis include 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BioVie (BIVIW), and Cardio Diagnostics (CDIOW).

How does Oculis compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Oculis (NASDAQ:OCSAW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Oculis N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Oculis. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Oculis. 60 Degrees Pharmaceuticals' average media sentiment score of 0.00 equaled Oculis'average media sentiment score.

Company Overall Sentiment
60 Degrees Pharmaceuticals Neutral
Oculis Neutral

Summary

60 Degrees Pharmaceuticals beats Oculis on 2 of the 2 factors compared between the two stocks.

How does Oculis compare to Alpha Tau Medical?

Oculis (NASDAQ:OCSAW) and Alpha Tau Medical (NASDAQ:DRTSW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

In the previous week, Oculis' average media sentiment score of 0.00 equaled Alpha Tau Medical'saverage media sentiment score.

Company Overall Sentiment
Oculis Neutral
Alpha Tau Medical Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
Alpha Tau MedicalN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
Alpha Tau Medical N/A N/A N/A

Summary

Oculis and Alpha Tau Medical tied by winning 0 of the 0 factors compared between the two stocks.

How does Oculis compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Oculis (NASDAQ:OCSAW) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Apollomics' average media sentiment score of 0.00 equaled Oculis'average media sentiment score.

Company Overall Sentiment
Apollomics Neutral
Oculis Neutral

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Oculis N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

Summary

Apollomics beats Oculis on 1 of the 1 factors compared between the two stocks.

How does Oculis compare to BioVie?

Oculis (NASDAQ:OCSAW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Oculis' average media sentiment score of 0.00 equaled BioVie'saverage media sentiment score.

Company Overall Sentiment
Oculis Neutral
BioVie Neutral

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
BioVie N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Summary

Oculis and BioVie tied by winning 0 of the 0 factors compared between the two stocks.

How does Oculis compare to Cardio Diagnostics?

Oculis (NASDAQ:OCSAW) and Cardio Diagnostics (NASDAQ:CDIOW) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
Cardio Diagnostics N/A N/A N/A

In the previous week, Oculis' average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company Overall Sentiment
Oculis Neutral
Cardio Diagnostics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
Cardio Diagnostics$16.57KN/AN/AN/AN/A

Summary

Cardio Diagnostics beats Oculis on 1 of the 1 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCSAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCSAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCSAW vs. The Competition

Export
MetricOculisPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$11.91B$7.04B$12.92B
Dividend YieldN/A2.69%2.58%10.20%
P/E RatioN/A788.55269.9524.78
Price / SalesN/A968.18650.49107.95
Price / CashN/A15.1228.8937.44
Price / BookN/A10.3211.256.43
Net IncomeN/A$2.77B$3.45B$347.27M
7 Day PerformanceN/A1.96%3.49%2.53%
1 Month Performance-12.11%-1.59%-0.66%-1.03%
1 Year Performance-36.45%191.11%77.20%23.28%

Oculis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCSAW
Oculis
N/A$4.50
flat		N/A-36.4%$0.00N/AN/A32
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
flat		N/A-77.2%$0.00$1.00MN/A2
DRTSW
Alpha Tau Medical
N/A$2.76
+20.7%		N/A+1,141.2%$0.00N/AN/A80
APLMW
Apollomics
N/A$0.02
-16.8%		N/A-28.1%$0.00$8.50MN/A59
BIVIW
BioVie
N/A$0.38
+8.3%		N/AN/A$0.00N/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OCSAW) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners
The ultimate IPO unicorn
Anthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...
Weiss Ratings | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
SpaceX is NOT the #1 IPO of 2026
A lesser known AI company is growing faster than both SpaceX and OpenAI. Its coding business reportedly grew f...
The Oxford Club | Sponsoredtc pixel
Beginner’s Guide to Gold
The Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This I...
Goldco Direct, LLC | Sponsoredtc pixel
China is not hedging. It's escaping.
China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...
Behind the Markets | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel